Literature DB >> 16392823

Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.

Huazhong He1, Danuta Zatorska, Joungnam Kim, Julia Aguirre, Laura Llauger, Yuhong She, Nian Wu, Robert M Immormino, Daniel T Gewirth, Gabriela Chiosis.   

Abstract

Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways. Its inactivation may result in targeting multiple molecular alterations and, thus, in reverting the transformed phenotype. The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone. The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented. The study identifies water soluble derivatives (>5 mM in PBS pH 7.4) of nanomolar potency (IC(50) approximately 50 nM) in cellular and animal models of cancer. Binding affinities of these compounds for Hsp90 correlate well with their biological activities. When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16392823     DOI: 10.1021/jm0508078

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  66 in total

1.  Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Authors:  Yiqun Jiang; Denzil Bernard; Yanke Yu; Yehua Xie; Tao Zhang; Yanyan Li; Joseph P Burnett; Xueqi Fu; Shaomeng Wang; Duxin Sun
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

2.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

Review 3.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

4.  Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines.

Authors:  Hui Tao; Yanlong Kang; Tony Taldone; Gabriela Chiosis
Journal:  Bioorg Med Chem Lett       Date:  2008-11-20       Impact factor: 2.823

5.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

6.  Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.

Authors:  Lisa Giulino-Roth; Herman J van Besien; Tanner Dalton; Jennifer E Totonchy; Anna Rodina; Tony Taldone; Alexander Bolaender; Hediye Erdjument-Bromage; Jouliana Sadek; Amy Chadburn; Matthew J Barth; Filemon S Dela Cruz; Allison Rainey; Andrew L Kung; Gabriela Chiosis; Ethel Cesarman
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

7.  Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Authors:  Hardik J Patel; Pallav D Patel; Stefan O Ochiana; Pengrong Yan; Weilin Sun; Maulik R Patel; Smit K Shah; Elisa Tramentozzi; James Brooks; Alexander Bolaender; Liza Shrestha; Ralph Stephani; Paola Finotti; Cynthia Leifer; Zihai Li; Daniel T Gewirth; Tony Taldone; Gabriela Chiosis
Journal:  J Med Chem       Date:  2015-04-22       Impact factor: 7.446

Review 8.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

9.  Total synthesis of cribrostatin 6.

Authors:  Daniel Knueppel; Stephen F Martin
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

10.  The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Authors:  Younghyun Lee; Huizi Keiko Li; Aya Masaoka; Shigeaki Sunada; Hirokazu Hirakawa; Akira Fujimori; Jac A Nickoloff; Ryuichi Okayasu
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.